{"id":66599,"date":"2026-05-28T21:27:29","date_gmt":"2026-05-28T13:27:29","guid":{"rendered":"https:\/\/flcube.com\/?p=66599"},"modified":"2026-05-28T21:27:30","modified_gmt":"2026-05-28T13:27:30","slug":"abbvie-secures-fda-approval-for-decnupaz-in-blastic-plasmacytoid-dendritic-cell-neoplasm-first-cd123-targeting-adc-addresses-ultra-rare-hematologic-malignancy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66599","title":{"rendered":"AbbVie Secures FDA Approval for DECNUPAZ in Blastic Plasmacytoid Dendritic Cell Neoplasm \u2013 First CD123-Targeting ADC Addresses Ultra-Rare Hematologic Malignancy"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>AbbVie Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>) announced on May 27, 2026, that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has approved <strong>DECNUPAZ (pivekimab sunirine-pvzy)<\/strong>, a <strong>CD123-targeting antibody-drug conjugate (ADC)<\/strong>, for the treatment of adult patients with <strong>blastic plasmacytoid dendritic cell neoplasm (BPDCN)<\/strong>. The approval addresses a critical unmet need in this ultra-rare and aggressive hematologic malignancy with historically limited therapeutic options.<\/p>\n\n\n\n<h2 id=\"h-regulatory-approval-summary\" class=\"wp-block-heading\">Regulatory Approval Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>AbbVie Inc. (NYSE: ABBV)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>DECNUPAZ (pivekimab sunirine-pvzy) \u2013 CD123-targeting ADC<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Approved Indication<\/strong><\/td><td>Adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>May 27, 2026<\/td><\/tr><tr><td><strong>Supporting Trial<\/strong><\/td><td>Phase 1\/2 CADENZA study<\/td><\/tr><tr><td><strong>Safety Warnings<\/strong><\/td><td>Boxed warning for hepatotoxicity including hepatic veno-occlusive disease<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-efficacy-data-cadenza-trial-results\" class=\"wp-block-heading\">Clinical Efficacy Data \u2013 CADENZA Trial Results<\/h2>\n\n\n\n<h3 id=\"h-newly-diagnosed-bpdcn-patients-n-33\" class=\"wp-block-heading\">Newly Diagnosed BPDCN Patients (n=33)<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Composite Complete Response Rate<\/strong><\/td><td>69.7%<\/td><\/tr><tr><td><strong>Median Duration of Response<\/strong><\/td><td>9.7 months<\/td><\/tr><tr><td><strong>Patients Proceeding to Stem Cell Transplant<\/strong><\/td><td>13 patients (39.4%)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-relapsed-refractory-bpdcn-patients-n-51\" class=\"wp-block-heading\">Relapsed\/Refractory BPDCN Patients (n=51)<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Composite Complete Response Rate<\/strong><\/td><td>15.7%<\/td><\/tr><tr><td><strong>Median Duration of Response<\/strong><\/td><td>9.2 months<\/td><\/tr><tr><td><strong>Patients Proceeding to Stem Cell Transplant<\/strong><\/td><td>6 patients (11.8%)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The data demonstrate clinically meaningful responses across both treatment-na\u00efve and heavily pretreated populations, with a substantial proportion of responders achieving sufficient disease control to proceed to potentially curative stem cell transplantation.<\/p>\n\n\n\n<h2 id=\"h-safety-profile-amp-risk-management\" class=\"wp-block-heading\">Safety Profile &amp; Risk Management<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Most Common Adverse Reactions (\u226520%):<\/strong> Edema, fatigue, musculoskeletal pain, hemorrhage, infusion-related reactions, nausea, and diarrhea<\/li>\n\n\n\n<li><strong>Boxed Warning:<\/strong> Hepatotoxicity, including hepatic veno-occlusive disease (VOD)<\/li>\n\n\n\n<li><strong>Additional Warnings:<\/strong> Infusion-related reactions, edema, sulfite allergic reactions, and embryo-fetal toxicity<\/li>\n\n\n\n<li><strong>Risk Evaluation and Mitigation Strategy (REMS):<\/strong> Likely required given boxed warning and serious adverse events<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-therapeutic-significance\" class=\"wp-block-heading\">Market Context &amp; Therapeutic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease Burden:<\/strong> BPDCN is an ultra-rare hematologic malignancy with estimated incidence of 0.04 cases per 100,000 population annually<\/li>\n\n\n\n<li><strong>Historical Treatment Landscape:<\/strong> Limited to intensive chemotherapy regimens with poor outcomes and high toxicity<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Median overall survival historically less than 12-18 months with conventional therapies<\/li>\n\n\n\n<li><strong>Therapeutic Innovation:<\/strong> First CD123-targeting ADC approved specifically for BPDCN<\/li>\n\n\n\n<li><strong>Target Rationale:<\/strong> CD123 (IL-3 receptor alpha) is highly expressed on BPDCN cells, providing tumor-selective targeting<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-outlook-amp-strategic-impact\" class=\"wp-block-heading\">Commercial Outlook &amp; Strategic Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Orphan Drug Designation:<\/strong> Qualifies for market exclusivity, tax credits, and other incentives<\/li>\n\n\n\n<li><strong>Pricing Premium:<\/strong> Ultra-rare indication supports premium pricing strategy typical of orphan oncology products<\/li>\n\n\n\n<li><strong>Market Size:<\/strong> Estimated 150-200 new BPDCN cases annually in the U.S., representing concentrated but high-value patient population<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Limited direct competition due to disease rarity and specialized nature of treatment<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Success supports AbbVie&#8217;s ADC platform and CD123-targeting approach for other hematologic malignancies<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding AbbVie&#8217;s DECNUPAZ commercial prospects, including market adoption, pricing, and competitive positioning. Actual results may differ due to risks including safety monitoring requirements, reimbursement challenges, market access barriers, and potential competitive developments in the ultra-rare hematologic malignancy space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie Inc. (NYSE: ABBV) announced on May 27, 2026, that the U.S. Food and Drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[234,35,853,15,24],"class_list":["post-66599","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-abbvie","tag-adc-xdc","tag-nyse-abbv","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AbbVie Secures FDA Approval for DECNUPAZ in Blastic Plasmacytoid Dendritic Cell Neoplasm \u2013 First CD123-Targeting ADC Addresses Ultra-Rare Hematologic Malignancy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AbbVie Inc. (NYSE: ABBV) announced on May 27, 2026, that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZ (pivekimab sunirine-pvzy), a CD123-targeting antibody-drug conjugate (ADC), for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The approval addresses a critical unmet need in this ultra-rare and aggressive hematologic malignancy with historically limited therapeutic options.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66599\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Secures FDA Approval for DECNUPAZ in Blastic Plasmacytoid Dendritic Cell Neoplasm \u2013 First CD123-Targeting ADC Addresses Ultra-Rare Hematologic Malignancy\" \/>\n<meta property=\"og:description\" content=\"AbbVie Inc. (NYSE: ABBV) announced on May 27, 2026, that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZ (pivekimab sunirine-pvzy), a CD123-targeting antibody-drug conjugate (ADC), for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The approval addresses a critical unmet need in this ultra-rare and aggressive hematologic malignancy with historically limited therapeutic options.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66599\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-28T13:27:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-28T13:27:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66599#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66599\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie Secures FDA Approval for DECNUPAZ in Blastic Plasmacytoid Dendritic Cell Neoplasm \u2013 First CD123-Targeting ADC Addresses Ultra-Rare Hematologic Malignancy\",\"datePublished\":\"2026-05-28T13:27:29+00:00\",\"dateModified\":\"2026-05-28T13:27:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66599\"},\"wordCount\":472,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AbbVie\",\"ADC \\\/ XDC\",\"NYSE: ABBV\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66599#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66599\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66599\",\"name\":\"AbbVie Secures FDA Approval for DECNUPAZ in Blastic Plasmacytoid Dendritic Cell Neoplasm \u2013 First CD123-Targeting ADC Addresses Ultra-Rare Hematologic Malignancy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-28T13:27:29+00:00\",\"dateModified\":\"2026-05-28T13:27:30+00:00\",\"description\":\"AbbVie Inc. (NYSE: ABBV) announced on May 27, 2026, that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZ (pivekimab sunirine-pvzy), a CD123-targeting antibody-drug conjugate (ADC), for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The approval addresses a critical unmet need in this ultra-rare and aggressive hematologic malignancy with historically limited therapeutic options.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66599#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66599\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66599#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Secures FDA Approval for DECNUPAZ in Blastic Plasmacytoid Dendritic Cell Neoplasm \u2013 First CD123-Targeting ADC Addresses Ultra-Rare Hematologic Malignancy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie Secures FDA Approval for DECNUPAZ in Blastic Plasmacytoid Dendritic Cell Neoplasm \u2013 First CD123-Targeting ADC Addresses Ultra-Rare Hematologic Malignancy - Insight, China&#039;s Pharmaceutical Industry","description":"AbbVie Inc. (NYSE: ABBV) announced on May 27, 2026, that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZ (pivekimab sunirine-pvzy), a CD123-targeting antibody-drug conjugate (ADC), for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The approval addresses a critical unmet need in this ultra-rare and aggressive hematologic malignancy with historically limited therapeutic options.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66599","og_locale":"en_US","og_type":"article","og_title":"AbbVie Secures FDA Approval for DECNUPAZ in Blastic Plasmacytoid Dendritic Cell Neoplasm \u2013 First CD123-Targeting ADC Addresses Ultra-Rare Hematologic Malignancy","og_description":"AbbVie Inc. (NYSE: ABBV) announced on May 27, 2026, that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZ (pivekimab sunirine-pvzy), a CD123-targeting antibody-drug conjugate (ADC), for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The approval addresses a critical unmet need in this ultra-rare and aggressive hematologic malignancy with historically limited therapeutic options.","og_url":"https:\/\/flcube.com\/?p=66599","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-28T13:27:29+00:00","article_modified_time":"2026-05-28T13:27:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66599#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66599"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie Secures FDA Approval for DECNUPAZ in Blastic Plasmacytoid Dendritic Cell Neoplasm \u2013 First CD123-Targeting ADC Addresses Ultra-Rare Hematologic Malignancy","datePublished":"2026-05-28T13:27:29+00:00","dateModified":"2026-05-28T13:27:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66599"},"wordCount":472,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AbbVie","ADC \/ XDC","NYSE: ABBV","Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66599#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66599","url":"https:\/\/flcube.com\/?p=66599","name":"AbbVie Secures FDA Approval for DECNUPAZ in Blastic Plasmacytoid Dendritic Cell Neoplasm \u2013 First CD123-Targeting ADC Addresses Ultra-Rare Hematologic Malignancy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-28T13:27:29+00:00","dateModified":"2026-05-28T13:27:30+00:00","description":"AbbVie Inc. (NYSE: ABBV) announced on May 27, 2026, that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZ (pivekimab sunirine-pvzy), a CD123-targeting antibody-drug conjugate (ADC), for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The approval addresses a critical unmet need in this ultra-rare and aggressive hematologic malignancy with historically limited therapeutic options.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66599#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66599"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66599#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie Secures FDA Approval for DECNUPAZ in Blastic Plasmacytoid Dendritic Cell Neoplasm \u2013 First CD123-Targeting ADC Addresses Ultra-Rare Hematologic Malignancy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66599"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66599\/revisions"}],"predecessor-version":[{"id":66600,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66599\/revisions\/66600"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}